The number of automatic external defibrillators (AEDs) and civilian first aid volunteers in the Netherlands increased sharply this past year. The Heart Foundation praises the people who followed a resuscitation course or purchased an AED with their neighborhood, AD reports.
Amsterdam football club Ajax admitted that it is liable for the condition of young player Abdelhak Nouri, general manager Edwin van der Sar announced in a press conference on Monday. Nouri's family is relieved that the club acknowledged its responsibility.
A federal court in the United States banned Philips from selling some of its medical devices, including defibrillators, until further notice. This ruling applies to the Philips factory in Andover and company managers Carla Kriwet and Ojas Buch. The ban will remain in effect until Philips makes improvements, Reuters reports.
A massive 170 thousand people in the Netherlands are registered with heart foundation Hartstichting as civilian aid workers able to help with a resuscitation. This makes the Netherlands the first country in the world with a "fine-grained and nationwide network of registered civilian aid workers who can resuscitate someone if called via a call system", the foundation said, RTL Nieuws reports.
All football matches must have a mandatory defibrillator available in future, according Michel D'Hooghe, physician and chairman of world football union FIFA's medical committee. If a defibrillator is handy, situations like Ajax player Abdelhak Nouri sustaining brain damage may be prevented, he believes, according to NOS.
The United States' Food and Drug Administration FDA recalled 47,362 Philips defibrillators because they may pose serious risks that may result in injury or even death, Financieele Dagblad reported on Wednesday. This is not actually a recall, only a warning of a minor problem with two defibrilators, a spokesperson for Philips said to the Telegraaf.
Philips is at loggerheads with American authorities over the production of defibrillators - FDA inspections revealed a number of shortcomings, according to ANP. The company is in talks with the U.S. department of Justice, acting on behalf of the FDA, on the matter. The company's value dropped by 4 percent after this was revealed on Tuesday morning.